Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

Cancer

Volumn 121, Issue 12, 2015, Pages 1949-1956

  Shui, Irene M ^a,b   Mondul, Alison M ^c,d   Lindström, Sara ^a   Tsilidis, Konstantinos K ^e,f   Travis, Ruth C ^e   Gerke, Travis ^a,g   Albanes, Demetrius ^c   Mucci, Lorelei A ^a,h   Giovannucci, Edward ^a,h   Kraft, Peter ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF IOANNINA   (Greece)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

circulating 25 hydroxyvitamin D; fatal prostate cancer; gene environment interaction; single nucleotide polymorphisms; vitamin D genes

Indexed keywords

25 HYDROXYVITAMIN D; CHOLESTANETRIOL 26 MONOOXYGENASE; RETINOID X RECEPTOR ALPHA; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; 25-HYDROXYVITAMIN D; VITAMIN D;

ARTICLE; CANCER GENETICS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CYP24A1 GENE; CYP27A1 GENE; CYP27B1 GENE; CYP2R1 GENE; GC GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RXRA GENE; SINGLE NUCLEOTIDE POLYMORPHISM; VDR GENE; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MORTALITY; NATIONAL HEALTH ORGANIZATION; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE; UNITED STATES;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; NATIONAL CANCER INSTITUTE (U.S.); POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMIN D;

EID: 84930374503     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29320     Document Type: Article

References (39)

1. Deeb KK, Trump DL, Johnson CS,. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7: 684-700.
2. Giovannucci E,. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005; 16: 83-95.
3. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ,. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14: 342-357.
4. Ahn J, Peters U, Albanes D, et al., Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008; 100: 796-804.
5. Travis RC, Crowe FL, Allen NE, et al., Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation Into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009; 169: 1223-1232.
6. Shui IM, Mucci LA, Kraft P, et al., Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012; 104: 690-699.
7. Albanes D, Mondul AM, Yu K, et al., Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1850-1860.
8. Gilbert R, Martin RM, Beynon R, et al., Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control. 2011; 22: 319-340.
9. Toriola AT, Nguyen N, Scheitler-Ring K, Colditz GA,. Circulating 25-hydroxyvitamin D levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014; 23: 917-933.
10. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC,. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-Up Study. Int J Cancer. 2007; 121: 1571-1578.
11. Fang F, Kasperzyk JL, Shui I, et al., Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011; 6: e18625.
12. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE,. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009; 100: 450-454.
13. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL,. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013; 37: 666-670.
14. Yin M, Wei S, Wei Q,. Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta-analysis of 36 published studies. Int J Clin Exp Med. 2009; 2: 159-175.
15. Ahn J, Albanes D, Berndt SI, et al., Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009; 30: 769-776.
16. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL,. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1929-1933.
17. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U,. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1990-1999.
18. Mondul AM, Shui IM, Yu K, et al., Genetic variation in the vitamin D pathway in relation to risk of prostate cancer-results from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2013; 22: 688-696.
19. Holt SK, Kwon EM, Koopmeiners JS, et al., Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010; 70: 1448-1460.
20. Schumacher FR, Berndt SI, Siddiq A, et al., Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011; 20: 3867-3875.
21. Li H, Stampfer MJ, Hollis JB, et al., A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4: e103.
22. International HapMap Consortium, Frazer KA, Ballinger DG, et al., A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449: 851-861.
23. Rosner B, Cook N, Portman R, Daniels S, Falkner B,. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol. 2008; 167: 653-666.
24. Wu MC, Kraft P, Epstein MP, et al., Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet. 2010; 86: 929-942.
25. Liu D, Ghosh D, Lin X,. Estimation and testing for the effect of a genetic pathway on a disease outcome using logistic kernel machine regression via logistic mixed models. BMC Bioinformatics. 2008; 9: 292.
26. Lin X, Cai T, Wu MC, et al., Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies. Genet Epidemiol. 2011; 35: 620-631.
27. Lin X, Lee S, Christiani DC, Lin X,. Test for interactions between a genetic marker set and environment in generalized linear models. Biostatistics. 2013; 14: 667-681.
28. Gao X,. Multiple testing corrections for imputed SNPs. Genet Epidemiol. 2011; 35: 154-158.
29. Kristal AR, Till C, Song X, et al., Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014; 23: 1494-1504.
30. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP,. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010; 19: 927-931.
31. Wang TJ, Zhang F, Richards JB, et al., Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010; 376: 180-188.
32. Tannour-Louet M, Lewis SK, Louet JF, et al., Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J. 2014; 28: 364-372.
33. Hendrickson WK, Flavin R, Kasperzyk JL, et al., Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011; 29: 2378-2385.
34. Ma J, Stampfer MJ, Gann PH, et al., Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 1998; 7: 385-390.
35. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E,. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007; 67: 911-923.
36. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA,. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005; 65: 5470-5479.
37. Bodiwala D, Luscombe CJ, French ME, et al., Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ Mol Mutagen. 2004; 43: 121-127.
38. Levin GP, Robinson-Cohen C, de Boer IH, et al., Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012; 308: 1898-1905.
39. 3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013; 98: 1498-1507.